JRJiankang Ren

Jiankang Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiankang Ren has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Haiyang Jiang

    State Key Laboratory of Veterinary Public Health and Safety, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China

    2 shared publications
  • Boyan Sun

    State Key Laboratory of Veterinary Public Health and Safety, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China

    1 shared publication
  • Chongshan Dai

    State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China

    1 shared publication
  • Chujun Liu

    State Key Laboratory of Veterinary Public Health and Safety, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China

    1 shared publication
  • Jianzhong Shen

    State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University

    1 shared publication
  • Jie Xie

    Technology Innovation Center of Mass Spectrometry for State Market Regulation, Center for Advanced Measurement Science, National Institute of Metrology, Beijing 100029, China

    1 shared publication

Latest Publications

  • Open Access

    Efficient Determination of β-Agonists in Environmental Water and Animal-Derived Matrices by NH2-UiO-66 Based d-SPE Coupled with UPLC-MS/MS: Performance, Mechanism and Application

    by Chujun Liu, Yuliang Xu, Sihan Wang, Boyan Sun, Zimo Liu, Qian Ran, Jiankang Ren, Zhiyue Feng, Jie Xie, Haiyang Jiang

    β-agonists are prohibited antibiotics that have raised concerns due to their illegal use in the livestock industry, posing potential toxicity risks to human health. For ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) analysis of β-agonists, effective sample pretreatment is a crucial and challenging process that dictates the overall reliability and sensitivity of the method. Thus, this study developed a reliable method utilizing dispersive solid-phase extraction (d-SPE) with NH2-UiO-66 as a superior adsorbent, coupled with UPLC-MS/MS, to extract and quantify β-agonists in environmental water, swine urine, and milk. The synthesized NH2-UiO-66 exhibited outstanding adsorption capacities (146.06–358.00 mg/g) towards the target analytes. The optimized method demonstrated excellent performance: low matrix effects (−13.10–15.30%), wide linearity (0.1–50 μg/L), low limits of detection (0.04–0.09 μg/L), and satisfactory recoveries (81.48–106.67%) with good precision (intra-day RSDs 1.51–6.24%; inter-day RSDs 2.06–10.96%). Adsorption mechanism studies revealed that the extraction process, which followed the Langmuir isotherm and pseudo-second-order kinetic models, was driven primarily by electrostatic interactions, π-π stacking, and hydrogen bonding. Moreover, the material could be reused up to 10 times, with satisfactory recoveries of 81.30% to 116.10%. The proposed NH2-UiO-66-d-SPE-UPLC-MS/MS protocol is generic and provides a robust and practical solution for monitoring trace β-agonists in animal-derived foods and environmental samples, ensuring food safety and environmental health.


  • Open Access

    Progress of AI-Driven Drug–Target Interaction Prediction and Lead Optimization

    by Qiqi Wang, Boyan Sun, Yunpeng Yi, Tony Velkov, Jianzhong Shen, Chongshan Dai, Haiyang Jiang

    In modern pharmaceutical research and development (R&D), drug discovery remains a challenging process. Artificial intelligence (AI) has been extensively incorporated into various phases of drug discovery and development. AI enable effectively extract molecular structural features, perform in-depth analysis of drug–target interactions, and systematically model the relationships among drugs, targets, and diseases. These approaches improve prediction accuracy, accelerate discovery timelines, reduce costs from trial and error methods, and enhance success probabilities. This review summarizes recent advances in AI applications for drug design, including target identification, synthetic accessibility prediction, lead optimization, and ADMET property evaluation. Furthermore, it introduces various deep learning tools to guide researchers in selecting and implementing the most appropriate AI-driven strategies throughout the drug discovery process. We hope it can establish a conceptual framework intended to advance AI-driven methodologies in pharmaceutical research by comprehensively organizing novel perspectives and critical insights.